多形性胶质母细胞瘤治疗市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024年，全球多形性胶质母细胞瘤治疗市场规模达36亿美元，预计2034年将以8.9%的复合年增长率成长至83亿美元。胶质母细胞瘤（GBM）发生率的上升是推动这一增长的主要因素。胶质母细胞瘤是一种高度侵袭性的脑肿瘤，起源于大脑半球，并迅速扩散至周围脑组织。随着研究与合作投入的增加，对新型治疗方法的开发日益重视，这正在显着重塑治疗模式。製药公司正投入大量资源来提高药物疗效和生物利用度，推动标靶治疗的发展，以应对GBM相关的复杂性和抗药性模式。这些进展不仅提高了治疗成功率，也使治疗更容易取得，更以患者为中心。

强劲的创新动能和策略伙伴关係正在稳步改变多形性胶质母细胞瘤的治疗格局，推动治疗标准朝着更个人化、针对性和高效的治疗方法发展。製药和生物技术公司正在积极与研究机构、临床中心和技术提供者合作，以加速新型治疗方案的开发。

此次合作聚焦精准医疗，旨在根据患者个别情况量身订做治疗方案，从而提高疗效并最大程度地减少不良反应。同时，先进诊断工具与即时监测解决方案的整合，使临床医生能够更精准地追踪病情进展并相应地调整治疗方案。这些进展不仅重新定义了治疗方案，还将在未来十年推动市场持续扩张方面发挥关键作用。

2024年，非药物治疗领域以24亿美元的估值领先市场，预计2034年将达到54亿美元，复合年增长率为8.5%。该领域的主导地位源于外科手术和放射疗法的日益普及，这些疗法在肿瘤控制方面具有很高的成功率。先进诊断工具和设备的不断发展加速了此类疗法的临床应用。患者越来越倾向于选择传统药物疗法的替代疗法，尤其是在药物抗药性以及噁心、免疫抑制和疲劳等副作用的挑战下。这些非药物疗法因其在有效控制肿瘤的同时最大程度地减少全身副作用而日益受到青睐。

医院领域占最大份额，2024 年达 44.3%，预计到 2034 年将达到 37 亿美元，复合年增长率为 9.1%。作为专科神经内科和肿瘤科护理的主要提供者，医院在提供全面的胶质母细胞瘤 (GBM) 治疗方面发挥着至关重要的作用。这些机构配备了尖端的影像系统、放射设备和神经外科平台，提供高度针对性和高效的护理。诊断率的不断上升，尤其是在医疗资源匮乏和发展中地区，加剧了人们对医院提供优质治疗的依赖。随着对公立和私人医疗基础设施投资的不断增加，医院作为临床研究和先进疗法实施中心的地位得到进一步加强。医院与製药公司之间的合作正在加速下一代治疗方案的引入，以改善疗效。

2024年，北美多形性胶质母细胞瘤治疗市场规模达15亿美元，预计2034年将达34亿美元，复合年增长率达8.6%。该地区受益于众多领先的製药公司和研究机构的坚实基础，这些公司和机构积极致力于癌症药物的研发。支持性政策框架、广泛的宣传活动以及强大的患者支持系统，都有助于提高治疗的采用率。临床试验可近性的提升以及免疫疗法的进步，进一步推动了整个非洲大陆市场的发展。

全球多形性胶质母细胞瘤治疗市场的主要活跃参与者包括 F. Hoffmann La Roche（基因泰克）、默克、辉瑞、Teva Pharmaceuticals、安进、Novocure、住友大日本製药、太阳製药工业、Karyopharm Therapeutics、NextSource Pharma、Azurity Pharmaceuticals、Curtanautical

胶质母细胞瘤 (GBM) 治疗领域的公司正优先投入研发资金，以加速创新疗法的开发，包括免疫疗法和标靶药物输送系统。与学术机构和生物技术公司的策略合作有助于扩大临床研究规模，并提高研发管线的成功率。各公司也专注于个人化医疗，整合基因组分析技术，提供客製化治疗方案。透过加速审批通道和孤儿药资格认定，新疗法的监管审批正在加速推进，从而提升市场准入率。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 胶质母细胞瘤发生率不断上升
    • 诊断和治疗方式的不断进步
    • 提高对疾病的认识和早期诊断
    • 肿瘤学研发投资不断增加
  • 产业陷阱与挑战
    • 即使治疗后胶质母细胞瘤復发率仍然很高
    • 治疗费用高昂
  • 市场机会
    • 新疗法的临床试验
    • 合作与策略联盟加速创新
• 成长潜力分析
• 技术景观
• 管道分析
• 未来市场趋势
• 监管格局
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 关键进展

第五章：市场估计与预测：按治疗类型，2021 - 2034 年

• 主要趋势
• 非药物治疗
  • 手术
  • 放射治疗
  • 肿瘤治疗场疗法
• 药物治疗
  • 按类型
    • 化疗
    • 标靶治疗
  • 按药物类别
    • 替莫唑胺
    • 贝伐单抗
    • 洛莫司汀
    • 卡莫司汀薄片
  • 按剂型
    • 口服
    • 肠外

第六章：市场估计与预测：依性别，2021 - 2034 年

• 主要趋势
• 男性
• 女性

第七章：市场估计与预测：依最终用途，2021 - 2034 年

• 主要趋势
• 医院
• 癌症治疗中心
• 门诊手术中心
• 其他最终用途

第八章：市场估计与预测：按地区，2021 - 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第九章：公司简介

• Amgen
• Amneal Pharmaceuticals
• Azurity Pharmaceuticals
• Curtana Pharmaceuticals
• Denovo Biopharma
• F. Hoffmann La Roche (Genentech)
• Karyopharm Therapeutics
• Merck
• NextSource Pharma
• Novocure
• Pfizer
• Sumitomo Dainippon Pharma
• Sun Pharmaceutical Industries
• Teva Pharmaceuticals

The Global Glioblastoma Multiforme Treatment Market was valued at USD 3.6 billion in 2024 and is estimated to grow at a CAGR of 8.9% to reach USD 8.3 billion by 2034. A major factor fueling this growth is the rising incidence of GBM, a highly aggressive form of brain tumor that originates in the cerebral hemisphere and spreads rapidly within surrounding brain tissue. The growing focus on developing novel therapeutic approaches, backed by increased investments in research and collaboration, is significantly reshaping the treatment landscape. Pharmaceutical companies are heavily channeling resources into improving drug efficacy and bioavailability, driving the development of targeted treatments that address the complexity and resistance patterns associated with GBM. These advances are not only enhancing treatment success rates but also making therapies more accessible and patient centric.

The strong momentum of innovation and strategic partnerships is steadily transforming the glioblastoma multiforme treatment landscape, steering the standard of care toward more personalized, targeted, and efficient therapeutic approaches. Pharmaceutical and biotechnology firms are actively collaborating with research institutions, clinical centers, and technology providers to accelerate the development of novel treatment regimens.

This collaborative focus on precision medicine results in therapies tailored to individual patient profiles, improving treatment efficacy and minimizing adverse effects. At the same time, the integration of advanced diagnostic tools and real-time monitoring solutions is enabling clinicians to track disease progression more accurately and adjust therapies accordingly. These developments are not only redefining treatment protocols but are also playing a crucial role in driving sustained market expansion over the coming decade.

In 2024, the non-pharmacological treatment segment led the market with a valuation of USD 2.4 billion and is anticipated to reach USD 5.4 billion by 2034, growing at a CAGR of 8.5%. The dominance of this segment stems from the growing adoption of surgical and radiation therapies, which deliver high success rates in tumor control. The continual evolution of advanced diagnostic tools and devices has accelerated the clinical utility of such treatments. Patient inclination is rising toward alternatives to conventional drug-based therapies, especially given the challenges of drug resistance and adverse effects like nausea, immune suppression, and fatigue. These non-drug treatments are gaining ground for offering effective tumor management while minimizing systemic side effects.

The hospital segment accounted for the largest share at 44.3% in 2024 and is forecasted to reach USD 3.7 billion by 2034 at a CAGR of 9.1%. As key providers of specialized neurology and oncology care, hospitals are central to the delivery of comprehensive GBM treatment. Equipped with cutting-edge imaging systems, radiation tools, and neurosurgical platforms, these facilities offer highly targeted and efficient care. The increasing diagnosis rates, particularly in underserved and developing regions, have amplified the reliance on hospitals for quality treatment. With growing investments in public and private healthcare infrastructure, hospital settings are further strengthened as hubs for clinical research and advanced therapy implementation. Collaboration between hospitals and pharmaceutical firms is accelerating the introduction of next-generation treatment protocols to improve outcomes.

North America Glioblastoma Multiforme Treatment Market was valued at USD 1.5 billion in 2024 and is expected to reach USD 3.4 billion by 2034 at a CAGR of 8.6%. The region benefits from a strong foundation of leading pharmaceutical players and research institutions actively engaged in cancer-focused drug development. Supportive policy frameworks, widespread awareness campaigns, and robust patient support systems are all contributing to heightened treatment adoption. Enhanced access to clinical trials and immunotherapy advancements further propels the market forward across the continent.

Key players active in the Global Glioblastoma Multiforme Treatment Market include F. Hoffmann La Roche (Genentech), Merck, Pfizer, Teva Pharmaceuticals, Amgen, Novocure, Sumitomo Dainippon Pharma, Sun Pharmaceutical Industries, Karyopharm Therapeutics, NextSource Pharma, Azurity Pharmaceuticals, Curtana Pharmaceuticals, Amneal Pharmaceuticals, Denovo Biopharma, and Johnson & Johnson.

Companies in the GBM treatment sector are prioritizing R&D investments to accelerate the development of innovative therapeutics, including immunotherapies and targeted drug delivery systems. Strategic collaborations with academic institutions and biotech firms are helping expand clinical research and improve pipeline success. Firms are also focusing on personalized medicine, integrating genomic profiling to offer customized treatment plans. Regulatory approvals for novel therapies are being fast-tracked through accelerated pathways and orphan drug designations, enhancing market entry.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional
  • 2.2.2 Treatment type
  • 2.2.3 Gender
  • 2.2.4 End use
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence of glioblastoma
    • 3.2.1.2 Growing advancements in diagnostic and treatment modalities
    • 3.2.1.3 Rising awareness and early diagnosis of disease
    • 3.2.1.4 Growing Investments in oncology research and development
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High recurrence rate of glioblastoma even after treatment
    • 3.2.2.2 High cost of treatment
  • 3.2.3 Market opportunities
    • 3.2.3.1 Clinical trials for novel therapies
    • 3.2.3.2 Collaborations and strategic alliances accelerate innovation
• 3.3 Growth potential analysis
• 3.4 Technology landcsape
• 3.5 Pipeline analysis
• 3.6 Future market trends
• 3.7 Regulatory landscape
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Key developments

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Non-pharmacological treatment
  • 5.2.1 Surgery
  • 5.2.2 Radiation therapy
  • 5.2.3 Tumor treating field therapy
• 5.3 Pharmacological treatment
  • 5.3.1 By type
    • 5.3.1.1 Chemotherapy
    • 5.3.1.2 Targeted therapy
  • 5.3.2 By durg class
    • 5.3.2.1 Temozolomide
    • 5.3.2.2 Bevacizumab
    • 5.3.2.3 Lomustine
    • 5.3.2.4 Carmustine wafers
  • 5.3.3 By dosage form
    • 5.3.3.1 Oral
    • 5.3.3.2 Parenteral

Chapter 6 Market Estimates and Forecast, By Gender, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Male
• 6.3 Female

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Cancer treatment centers
• 7.4 Ambulatory surgical centers
• 7.5 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Amgen
• 9.2 Amneal Pharmaceuticals
• 9.3 Azurity Pharmaceuticals
• 9.4 Curtana Pharmaceuticals
• 9.5 Denovo Biopharma
• 9.6 F. Hoffmann La Roche (Genentech)
• 9.7 Karyopharm Therapeutics
• 9.8 Merck
• 9.9 NextSource Pharma
• 9.10 Novocure
• 9.11 Pfizer
• 9.12 Sumitomo Dainippon Pharma
• 9.13 Sun Pharmaceutical Industries
• 9.14 Teva Pharmaceuticals